AYTU BIOPHARMA, INC Quarterly Debt-to-equity in % from Q4 2015 to Q3 2023

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Aytu Biopharma, Inc quarterly Debt-to-equity history and growth rate from Q4 2015 to Q3 2023.
Aytu Biopharma, Inc Debt-to-equity for the quarter ending September 30, 2023 was 253 %, a 55.6% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2023	253	+90.3	+55.6%	Sep 30, 2023
Q2 2023	230	+94.7	+70.1%	Jun 30, 2023
Q1 2023	221	+108	+95.6%	Mar 31, 2023
Q4 2022	200	+101	+102%	Dec 31, 2022
Q3 2022	162	+77.8	+92%	Sep 30, 2022
Q2 2022	135	+60.6	+81.4%	Jun 30, 2022
Q1 2022	113	+47.3	+71.8%	Mar 31, 2022
Q4 2021	98.7	+37.3	+60.9%	Dec 31, 2021
Q3 2021	84.5	+1.75	+2.11%	Sep 30, 2021
Q2 2021	74.5	-34.3	-31.5%	Jun 30, 2021
Q1 2021	65.8	-101	-60.5%	Mar 31, 2021
Q4 2020	61.3	-258	-80.8%	Dec 31, 2020
Q3 2020	82.8	-140	-62.9%	Sep 30, 2020
Q2 2020	109	-42.3	-28%	Jun 30, 2020
Q1 2020	167	+65.3	+64.4%	Mar 31, 2020
Q4 2019	320	+233	+270%	Dec 31, 2019
Q3 2019	223	+116	+109%	Sep 30, 2019
Q2 2019	151	+13.3	+9.66%	Jun 30, 2019
Q1 2019	101	-98.9	-49.4%	Mar 31, 2019
Q4 2018	86.5	-138	-61.4%	Dec 31, 2018
Q3 2018	107	-44.6	-29.5%	Sep 30, 2018
Q2 2018	138	-3.08	-2.19%	Jun 30, 2018
Q1 2018	200	+74.1	+58.7%	Mar 31, 2018
Q4 2017	224	+130	+138%	Dec 31, 2017
Q3 2017	151	+69.7	+85.5%	Sep 30, 2017
Q2 2017	141	+77.3	+122%	Jun 30, 2017
Q1 2017	126	+87.2	+224%	Mar 31, 2017
Q4 2016	94.4	+29	+44.4%	Dec 31, 2016
Q3 2016	81.5			Sep 30, 2016
Q2 2016	63.5			Jun 30, 2016
Q1 2016	39			Mar 31, 2016
Q4 2015	65.4			Dec 31, 2015

* An asterisk sign (*) next to the value indicates that the value is likely invalid.